Fabian Kausche

Villigen, Switzerland, Feb. 24, 2026 (GLOBE NEWSWIRE) —

• Dr. Fabian Kausche, a distinguished animal health executive, joins ASTRA Therapeutics to strengthen strategic leadership and long-term value creation.
• Appointment reinforces ASTRA Therapeutics’ commitment to building a scalable, globally competitive animal health company focused on precision anti-parasitic innovation.
• Board strengthened ahead of future value-creation phases, including strategic partnerships and Series A financing.

Villigen, Switzerland, 24 February 2026 – ASTRA Therapeutics AG today announced the appointment of Dr. Fabian Kausche as Chairman of its Board of Directors, reinforcing the company’s governance and strategic leadership as it advances its precision parasitology platform toward global scale.

Fabian Kausche brings decades of executive leadership across animal and human health, with deep expertise in R&D governance, portfolio strategy, and organizational transformation. He has repeatedly led large, multinational R&D organizations through growth, integration, and strategic repositioning. Complementing this corporate background, he also brings hands-on startup and transaction experience, having served as Chairman of the Board of PetMedix and guiding the company through its strategic development and successful acquisition by Zoetis. This combination of global leadership and entrepreneurial value-creation experience provides highly relevant strategic perspective and makes him an ideal leader for ASTRA Therapeutics as it advances toward its next phase of growth.

“Fabian’s leadership experience at the highest levels of global animal health R&D brings exactly the strategic depth we need at this stage. His ability to build high-performing teams and align innovation with disciplined governance will be instrumental as we continue advancing ASTRA Therapeutics’ mission to redefine precision in parasitology,” said Natacha Gaillard, PhD, Co-Founder and Co-CEO of ASTRA Therapeutics.

Fabian Kausche commented: “ASTRA Therapeutics combines scientific differentiation with a clear strategic vision. The company’s precision approach to parasitology directly addresses one of the most urgent challenges in animal health – resistance to existing therapies. I look forward to working closely with the team to strengthen governance, advance the pipeline, and help realize the company’s long-term potential.”

Following the successful closing of its CHF 7.75 million seed financing round in July 2025, ASTRA Therapeutics is deliberately strengthening its Board of Directors and governance framework to support scaling, global partnerships, and future capital formation. The company is building the institutional foundation required to translate its ParaX^® platform into differentiated, globally competitive animal health products and durable shareholder value.

Ashwani Sharma, PhD, Co-Founder and Co-CEO of ASTRA Therapeutics, added: “As we advance our pipeline and prepare for our Series A financing, it is essential that our governance evolves in step with our scientific progress. Fabian’s track record in managing multi-billion-dollar R&D organizations and leading complex integrations provides strong strategic guidance as we position ASTRA Therapeutics for disciplined growth, successful capital formation, and sustained long-term value creation.”

Contact

Beatrix Benz
+41 79 256 77 73
media@astratherapeutics.com

About Dr. Fabian Kausche

Fabian Kausche brings several decades of senior executive experience in animal and human health research and development. He previously served as Global Head of R&D for Novartis Animal Health, Merial, and Boehringer Ingelheim Animal Health, where he led large multinational organizations and oversaw the integration of the industry’s largest R&D structure.

His track record spans innovation strategy, R&D governance, portfolio optimization, and organizational transformation, with a strong focus on aligning scientific excellence with sustainable business growth. He currently leads FK Consulting, LLC, advising private equity firms, venture funds, and growth-stage companies on product innovation, governance structures, and operational effectiveness.

Fabian Kausche also served as Deputy Director General for Research and Innovation at the International Livestock Research Institute (ILRI) in Nairobi, leading global research initiatives to address livestock health challenges in emerging markets. He holds multiple board and advisory roles across the global animal health ecosystem.

He holds a veterinary degree from the University of Veterinary Medicine Hannover, an M.Sc. from Iowa State University, and a German PhD (Dr. med. vet.). Having completed the Advanced Management Program, he is also an alumni of Harvard Business School.

About Astra Therapeutics AG

ASTRA Therapeutics is a Swiss biotechnology company based at the Park InnovAARE innovation campus in Villigen, Switzerland that designs novel precision drugs against eukaryotic pathogens based on its proprietary platform ParaX^®, with a focus on applications in Animal Health.

The company is backed by MIG Capital AG, a leading German venture capital firm, alongside US-based Digitalis Ventures and Borealis Ventures, as well as Kickfund, and Venture Kick.

For more information, please visit www.astratherapeutics.com

Attachments

• Fabian Kausche
• ASTRA_Press Release_Chair_Final_260224

Direxion Delivers Four New 2X Bull Single Stock Leveraged ETFs for High Conviction Stock Traders

New York, United States, Feb. 24, 2026 (GLOBE NEWSWIRE) — New ETFs Tied to ASML, BABA, MRVL, and SOFI Bring Direxion’s Single Stock Leveraged & Inverse Suite to 55 Fund Offerings

Direxion, the leader in Single Stock Leveraged & Inverse ETFs, today announced four new ETFs, offering 2X daily amplified exposure to ASML Holding (ASML), Alibaba Group (BABA), Marvell Technology, Inc. (MRVL), and SoFi Technologies Inc. (SOFI). These funds provide traders with targeted tools to express short-term bullish views on some of the market’s most actively traded semiconductor, e-commerce, and digital finance companies.

The new ETFs include:

• Direxion Daily ASML Bull 2X ETF (Ticker: ASMU)
• Direxion Daily BABA Bull 2X ETF (Ticker: BABU)
• Direxion Daily MRVL Bull 2X ETF (Ticker: MRVU)
• Direxion Daily SOFI Bull 2X ETF (Ticker: SOFA)

“These companies sit at the core of the digital economy – from the chips and networks powering AI and cloud computing, to the platforms enabling global e-commerce and digital finance,” said Mo Sparks, Chief Product Officer of Direxion. “Our new Single Stock Leveraged ETFs give traders precise tools to express short-term views on the stocks driving these critical growth trends.”

With the launch of these four funds, Direxion now offers 55 single stock ETFs, spanning a wide range of sectors, including technology, e-commerce, energy, aerospace, semiconductors, automotive. This breadth gives traders the flexibility to target specific names driving market momentum. 

All Direxion Leveraged and Inverse ETFs are intended only for investors with an in-depth understanding of the risks associated with seeking leveraged investment results, and who plan to actively monitor and manage their positions. There is no guarantee these ETFs will meet their objective. Please visit the Direxion Leveraged and Inverse ETF Education Center, where you will find educational brochures, videos, and a self-paced online course to help you understand if Leveraged and Inverse ETFs – including Single Stock Daily LETFs – are right for you.

About Direxion:

Direxion equips investors who are driven by conviction with ETF solutions built for purpose and fine-tuned for precision. These solutions are available for a broad spectrum of investors, whether executing short-term tactical trades, or investing in thematic strategies. Direxion’s reputation is founded on developing products that precisely express market perspectives and allow investors to manage their risk exposure. Founded in 1997, the company has approximately $54.8 billion in assets under management as of December 31, 2025. For more information, please visit www.direxion.com.  

There is no guarantee that the Funds will achieve their investment objectives.

For more information on all Direxion Shares ETFs, go to www.direxion.com, or call us at 866.301.9214.

An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a prospectus and summary prospectus call 866.476.7523 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing.

Investing in the funds involves a high degree of risk. Unlike traditional ETFs, or even other leveraged and/or inverse ETFs, these leveraged and/or inverse single-stock ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. Leveraged and inverse ETFs pursue daily leveraged investment objectives, which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying stock’s performance over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments. The Funds will lose money if the underlying stock’s performance is flat, and it is possible that the Bull Fund will lose money even if the underlying stock’s performance increases, and the Bear Fund will lose money even if the underlying stock’s performance decreases, over a period longer than a single day. Investing in the Funds is not equivalent to investing directly in the underlying stock.

Direxion ETF Risks – An investment in the ETFs involves risk, including the possible loss of principal. The ETFs are non-diversified and include risks associated with concentration that results from an ETF’s investments in a particular industry, sector or security which can increase volatility. The use of derivatives such as futures contracts and swaps are subject to market risks that may cause their price to fluctuate over time. The ETFs do not attempt to, and should not be expected to, provide returns which are a multiple or inverse of the return of their respective underlying security for periods other than a single day. For other risks including leverage, correlation, daily compounding, market volatility and risks specific to an industry or sector, please read the prospectus.

Distributor: ALPS Distributors, Inc. 

Attachment

• Direxion Delivers Four New 2X Bull Single Stock Leveraged ETFs for High Conviction Stock Traders

CONTACT: Associate Vice President
Danielle Black
Ditto Public Relations
direxion@dittopr.co

SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) — AI/R today announced the availability of Llia in the Microsoft Marketplace, the unified online destination for customers to buy trusted cloud solutions, AI apps, and agents to meet their business needs. AI/R’s customers can now discover and deploy trusted solutions through Microsoft Marketplace, with smooth integration and streamlined management across Microsoft Azure and other Microsoft products.

A reference in Agentic AI applied to software engineering and digital acceleration, AI/R now expands its reach within the Microsoft ecosystem with the availability of Llia, its intelligent AI agent designed to transform recruitment operations. Llia leverages advanced language models, autonomous workflows, and native integration with corporate systems to evaluate candidates, automate screenings, generate insights, and substantially reduce time-to-hire. Companies using Llia report hiring cycles up to three times faster and recruitment costs reduced by as much as 80%, while improving candidate and recruiter experience through streamlined, always‑available AI‑driven interactions.

“The arrival of Llia on the Microsoft Marketplace marks an important milestone in AI/R’s mission to democratize high‑impact Agentic AI. Llia was engineered to solve one of the most critical challenges organizations face—hiring better and faster—and now it is available in a secure, trusted, and fully integrated Microsoft environment. We’re excited to empower even more companies around the world with this capability,” says Alexis Rockenbach, Global CEO of AI/R.

“Microsoft Marketplace helps organizations and partners move faster, work smarter, and grow by connecting them with the right solutions—all in one trusted place,” said Cyril Belikoff, vice president, Microsoft Azure Product Marketing. “We’re happy to welcome AI/R’s solution to the growing Microsoft Marketplace ecosystem.”

Microsoft Marketplace is a single destination to find, try, and buy trusted cloud solutions, AI apps, and agents to meet your business objectives. Choose from a growing collection of solutions tailored to your unique needs, available both in Marketplace and directly within Microsoft products.

About AI/R
AI/R, headquartered in California, is an Agentic AI Software Engineering company that combines its ecosystem of highly specialized technology brands, proprietary AI platforms, and strategic partner platforms to amplify human intelligence and drive a revolution across industries, setting efficient standards for innovation and business productivity. By embedding AI into every aspect of its operations, AI/R’s mission is to make the AI revolution a revolution for everyone, empowering human talent while raising the bar for digital transformation. Let’s breathe in the future.

Milena Buarque Lopes Bandeira, milena.bandeira@aircompany.ai  

The new location totals approximately 19,000 square feet and is positioned at the corner of Route 1 and Occoquan Road, just two blocks from Salvation Army’s previous site. The center offers strong traffic counts, excellent visibility, and prominent pylon signage.

The relocation follows the closure of Gordon Plaza, which is slated for demolition as part of a redevelopment that will include a new Home Depot, expected to deliver in 2027. The move allows Salvation Army to remain in the Woodbridge corridor while upgrading to a stronger retail setting.

Woodbridge Shopping Center is co-anchored by CVS and Dixie Bones, providing Salvation Army with a high-traffic environment alongside nationally recognized retailers.

The long-term lease reflects Salvation Army’s long-term plans in the market. The store opened ahead of the holiday season.

Salvation Army is a nonprofit organization specializing in thrift retail, with proceeds supporting community programs and social services. Thrifting continues to grow in popularity across all generations.

Boosalis Properties represented the landlord in the transaction. 

“We’re excited to represent the landlord in this transaction,” said George Boosalis. “Salvation Army is a strong anchor and an excellent co-anchor for CVS. It will drive traffic to the shopping center, benefit co-tenants, and serve the surrounding community.”

Salvation Army – Woodbridge Shopping Center
Salvation Army’s new, highly visible location at the corner of Route 1 and Occoquan Road, positioned in a strong retail environment alongside national co-anchors.

Interior View | Woodbridge Shopping Center
Inside the newly opened Salvation Army location at Woodbridge Shopping Center, approximately 19,000 SF serving the local community.

Media Contact:
Maria Sarantis
Communications Director, Boosalis Properties
maria@boosalisproperties.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/804e36c6-ac48-44a7-add3-e4adb76b6bae

https://www.globenewswire.com/NewsRoom/AttachmentNg/e9b34c80-f926-4522-9a84-b300c4867505

NEWARK, N.J., Feb. 22, 2026 (GLOBE NEWSWIRE) — Every day, millions of men put in hours of work while standing on hard surfaces. All that pain and pressure on joints, muscles, and padding lead to swollen feet and fatigue that make it much harder to feel motivated the next day. To combat the unforgiving nature of hard surfaces on feet, international performance footwear brand FitVille unveiled a new solution for long-term comfort: the Men’s Cloud Strider V3.

Relief for the feet is crucial not only for those who spend hours on end helping customers, providing services, or conducting meetings, but also for productivity. Buyers who want a little more TLC for their feet are on the hunt for the most comfortable walking shoes for standing all day, and the Cloud Strider V3 offers a blend of therapeutic design, ergonomic engineering, and performance-driven aesthetics that meet that mark.

A Brand Focused on Solving Real Foot Pain

FitVille has built a reputation for comfort-driven solutions in modern footwear since its founding in 2018. The brand’s founder struggled to find running shoes that fit truly wide feet without causing unwanted pressure on joints or instability when walking. That challenge sparked a design philosophy that liberates movement rather than makes wearers feel overly restricted.

Today, all FitVille products meet the three core pillars of therapeutic functionality, advanced comfort technology, and structural support innovation, especially for consumers aged 35-65 who are dealing with foot fatigue, swelling, knee strain, and other common issues.

“We started this journey on the idea that footwear should feel great and provide support for more people,” says ( James , CEO of the FitVille ). “With the Cloud Strider V3, we’ve found an exceptional product that will help men seize the day and not feel like they need to soak their feet for hours on end when home.”

Wide Fit Shoes Engineered for Wide Feet

One of the defining features of the newly announced FitVille Cloud Strider V3 is its inclusive size range. These are the most comfortable walking shoes available in sizes Wide (2E) and Extra Wide (4E) for men.

The design of the Cloud Strider V3 doesn’t feel bulky or chemical like other products on the market. The toe box has an extended space to allow more natural toe splay and to reduce friction while using the feet for balance during a prolonged workday of standing at a counter, workbench, or standing desk.

Features Any Man Can Enjoy

With the FitVille Cloud Strider V3, many concerns about wider feet, bunions, arthritis, or hammer toes are alleviated. The entire design is suitable for those passionate about running, but it also works just as well for the most comfortable walking trainers around the house doing chores, or at the office catching up on work. Features of the newly announced comfort shoes include:

• Support for wide feet and high insteps
• Zero break-in time with a soft, breathable upper, cushy collar, and bouncy sole
• Arch support with extra bounce through ArchCore insoles
• Fatigue-free steps using the WidePlatform that evenly distribute weight
• A thick sole to prevent toe bending and provide immediate relief
• Wide toe box to alleviate discomfort or pinching
• Slip resistance traction for improved control
• Adjustable closures or laces to fit varying foot shapes and widths
• Lightweight design that reduces overall stress on the feet and joints

From the breathable knit upper to ensure greater airflow when walking the family dog to soft padding interior for a plush and supportive feel, your feet will appreciate the Cloud Strider V3’s unique design. The most comfortable walking shoes for standing all day need to offer exceptional shock absorption and stability, and this latest model from FitVille ensures a cushy stride that minimizes impact on the wearer’s joints.

Designed for Practical Foot Comfort

Unlike performance runners built solely for sport, the FitVille Cloud Strider V3 thrives in everyday environments. It is designed with American ingenuity to address a range of scenarios and ensure proper protection. That includes a thick, cushioned EVA midsole and a high-rebound EVA foam with a slip-resistant, patterned outsole.

“Feet take us everywhere,” continues ( James , CEO of the FitVille ). “FitVille wants to ensure our customers can meet their daily needs without sacrificing a comfortable, therapeutic fit that meets any mobility demand.”

In the arena of everyday work, the Cloud Strider V3 helps prevent wear and tear on joints and feet during healthcare shifts, moving from patient room to patient room, or standing all day on hardwood floors in an upscale retail shop. Warehouse employees will appreciate the shoes’ breathability as much as those commuting to offices who want the most comfortable walking trainers to ensure a smooth journey.

The benefits of the Cloud Strider V3 don’t end at work. Running errands like picking up groceries for the night’s family dinner or meeting up with friends at a local coffee shop is much easier. The shoe offers superior support, making cleaning up the kitchen, picking up the kids, or traveling to new destinations a cinch.

FitVille also took the time to ensure men with wider feet get support during daily exercise. Everything from a stroll through the park to walking the dog or getting in an early morning light jog is well supported by these comfortable, wide-fit shoes.

A Step Forward Toward Pain-Free Living

Whenever discussions about improving one’s health or meeting productivity come up, footwear is often left out of the conversation. FitVille seeks to interrupt that interaction by providing the most comfortable walking shoes, versatile enough to improve work life, home activities, and social gatherings.

With advanced impact absorption, a breathable construction, and structured arch support, including for wider feet, the Cloud Strider V3 delivers a holistic mobility solution for men dealing with long shifts and chronic foot conditions.

The FitVille Men’s Cloud Strider V3 hits the market in late February 2026, providing a supportive, structured, and aesthetically designed solution to step up any comfort game. Men seeking foot fatigue relief, especially for wider feet, can find more information at the official FitVille website. Now is the best time to keep feet healthy, no matter where people are moving next, and FitVille is here to help.

About FitVille:

FitVille is an ergonomic performance footwear brand committed to improving functional mobility and comfort using therapeutic, structured support. Inspired by the idea that everyone deserved pain-free movement, the brand designs solutions for wide feet, sensitive conditions, and those seeking a more comfortable lifestyle. Learn more by visiting the official FitVille website at.

Contact Information:

Website: https://thefitville.com/

CEO: James D Kuai

Address: 2035 Sunset Lake Road, Suite B-2, Newark, Delaware

Email: contact@thefitville.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4fe059b8-1ba1-4fea-9c44-37dc9fb6382d

https://www.globenewswire.com/NewsRoom/AttachmentNg/25a85a77-48f1-4e16-a2dd-3e961e94b759

KUALA LUMPUR, Malaysia and RICHARDSON, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) — Tune Talk, one of Malaysia’s most recognized mobile brands, has completed its evolution into a fully independent, cloud-native mobile network operator (MNO) through a strategic partnership with Mavenir, the network software provider building AI‑driven mobile infrastructure. The deployment enables Tune Talk to operate its own network systems end‑to‑end, unlocking new speed, agility, and innovation capabilities ahead of its next phase of growth.

The shift has been enabled by adopting Mavenir’s cloud-native OSS and BSS solutions, giving Tune Talk full control of its network operations and digital service platforms, and providing a software-driven foundation for future growth.

By modernising its OSS and BSS layers with Mavenir’s cloud‑native platforms, Tune Talk now operates an independent, software‑defined network. This upgrade enables faster service deployment, more personalised AI‑driven customer experiences, and improved network reliability.

The new architecture has already accelerated the rollout of digital services, including MyDigital ID integration, Mastercard ID Theft Protection, free Personal Accident Insurance, foodpanda benefits, and in‑app streaming content such as drama and game subscriptions.

Tune Talk’s new cloud-native operational environment features zero-touch processes and self-healing automation, improving network stability while reducing operational overheads.

Phase two will deepen Tune Talk’s AI‑driven transformation, introducing advanced orchestration, next-generation BSS. These capabilities will further enhance network performance, accelerate service delivery, and unlock new revenue streams through contextual, personalised offers.

“Becoming a fully cloud-native MNO marks the start of a new chapter for Tune Talk and reinforces our ambition to build a smarter, more agile mobile network for Malaysia and beyond,” said Tune Talk CEO Gurtaj Singh Padda. “These foundations enable us to move faster, personalise services at scale, and unlock new value through AI-driven innovation for our growing customer base.”

“We’re proud to have successfully delivered this first phase of our partnership with Tune Talk, advancing their evolution as a fully cloud-native MNO,” said Mavenir President and CEO Pardeep Kohli. “The Tune Talk team is committed to constant innovation, always pushing boundaries to deliver for their customers – our fully cloud-native approach is essential to enabling the speed, flexibility and efficiency they rely on to keep delivering.”

With this deployment, Tune Talk becomes a reference model for cloud-native MNO operations not just in Malaysia but to also the ASEAN region, demonstrating how modern OSS/BSS architectures can accelerate operator independence, agility, and long-term digital transformation.

Join the conversation at Mobile World Congress in Barcelona #MWC26:   

Mavenir, in collaboration with Mobile World Live, will host a panel discussion at MWC26, “Built for More, Bound by Less: The rise of a new breed of MNO embracing AI, Cloud & 5G” on Mavenir’s stand in Hall 2, 2H60 – Monday 2^nd March at 01:15 – 01:45 PM. Featuring Tune Talk’s CEO Gurtaj Singh Padda, alongside an executive speaker  from TextNow, and Mavenir’s Sandeep Singh, the session will highlight how mobile networks thrive when they combine cloud-native architectures, AI-driven insight, and flexible monetization, offering practical tactics to differentiate on experience rather than price.

To join in-person or via live streaming, please register here:
Built for More, Bound by Less: The Rise of a New Breed of MNO Embracing AI, Cloud & 5G

About Mavenir 

Mavenir is enabling intelligent, automated, programmable networks through the development of telco-first, cloud-native, AI-by-design software solutions for mobile operators. The company’s deep telco domain expertise has been proven through deployments with 300+ operators globally in over 120 countries, which together serve more than 50% of the world’s subscribers. Mavenir combines its deep telco experience with the cloud and IT expertise and data science skillsets essential to solving real customer challenges. Its proven software solutions are AI by design, delivering the AI-native future and operators’ evolution to TechCos. 

For more information, please visit www.mavenir.com 

Mavenir PR Contacts: 
Emmanuela Spiteri 
PR@mavenir.com 

About Tune Talk

Tune Talk is the fastest-growing fully cloud native Mobile Network Operator in Asia. Since our launch in 2009, we have remained committed to offering affordable rates and exciting incentives. As a digital lifestyle telecommunications company, our services include unlimited calls, SMS, and high-speed internet packages, tailored to meet the demands for simple, value-driven products with easy accessibility and wide distribution. Our focus on innovation and digital disruption drives us to continuously provide cutting-edge telecommunication solutions, meeting the evolving needs of our customers, and keeping us at the forefront of the industry.

For more information, please visit www.tunetalk.com.

For media inquiries, please contact:
Brand representative
 • Ahmad Zhafir Zulkifili
Mobile: +60 17-252 0315
Email: zhafir.zulkifili@tunetalk.com

Team Continuum PR
 • Michelle Bridget
Mobile: +60 12-697 7356
Email: michelle.bridget@continuumpr.com
 • Kashantha Ravindran
Mobile: +60 16-976 2767
Email: kashantha@continuumpr.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a6112464-73e8-471f-a807-aae31298e49a

Austin, TX, Feb. 22, 2026 (GLOBE NEWSWIRE) — infoCorvus today announced the continued evolution of its ROAD platform, a unified data lifecycle control plane designed to help large enterprises govern data, reduce risk, and enable AI safely at scale. 

As organizations accelerate AI adoption, many are discovering a hard truth: AI systems amplify existing data risks just as efficiently as they unlock new value. Fragmented pipelines, legacy applications, and inconsistent governance models expose enterprises to compliance failures, security gaps, and uncontrolled AI behavior. infoCorvus addresses this challenge with a clear operating philosophy—Trust is built through Control. 

ROAD operationalizes that philosophy by embedding governance directly into the data lifecycle, rather than treating it as an afterthought. The platform unifies data ingestion, migration, application retirement, governance, and AI enablement into a single governed architecture—allowing organizations to modernize incrementally while maintaining continuous control over both live and historical structured data. 

“Most enterprises are trying to enable AI on top of foundations that were never designed for it,” said Ali Elkortobi, CEO of infoCorvus. “ROAD gives organizations a practical way to regain control of their data first—so AI becomes an asset, not a liability. Govern Data. Reduce Risk. Enable AI. At Scale.” 

That scale is not theoretical. In a competitive evaluation, a large global manufacturer with decades-old, highly complex systems selected ROAD after requiring proof across performance, governance, and operational simplicity. The organization manages more than 200 billion rows of enterprise data and archives over 100 million rows every month, while maintaining full auditability, lineage, and policy enforcement across retired and active environments. ROAD delivered sustained throughput without custom code, validating its ability to operate reliably on a global enterprise scale. 

A core component of this architecture is the Governed AI Bridge, which ensures that AI systems only access approved, lineage-tracked, policy-compliant enterprise data. Rather than exposing operational systems or unmanaged datasets directly to models, the Governed AI Bridge enforces decision rights, access controls, and evidence at execution time—providing enterprises with defensible AI operations aligned with regulatory and security requirements. 

By consolidating traditionally siloed initiatives into a single governed platform, ROAD reduces implementation complexity, lowers long-term operating costs, and shrinks audit and security exposure. Organizations typically realize millions of dollars in annual cost avoidance through safe application retirement, while establishing a trusted data foundation capable of supporting analytics, automation, and AI initiatives for the long term. 

Availability 

ROAD is available now for enterprise deployment across cloud and on-premises environments. Organizations facing application retirement, data modernization, or AI governance challenges can request a technical consultation and live demonstration at www.infoCorvus.com. 

About infoCorvus 

infoCorvus provides Data Lifecycle Management solutions that help enterprises govern data pipelines end-to-end—retiring legacy systems, enforcing data governance, reducing compliance and security risk, and enabling AI safely at scale. 

Media Contact 

Press Relations — infoCorvus 

info@infoCorvus.com 

www.infoCorvus.com 

Press Inquiries

Jan Brown
jan.brown@infocorvus.com
https://infocorvus.com

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) manufacturing for Inovio’s CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

Important Deadline Reminder: Investors who purchased or otherwise acquired Oracle common stock during the Class Period may, no later than April 6, 2026, move the Court to serve as lead plaintiff for the class.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
If you experienced losses in connection with Oracle, contact Kessler Topaz Meltzer & Check, LLP at:
https://www.ktmc.com/orcl-oracle-corporation-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=orcl&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com.

DEFENDANTS’ ALLEGED MISCONDUCT
Oracle, a Delaware corporation with its principal executive offices in Austin, Texas, is a technology company that provides, among other things, infrastructure for operating artificial intelligence (“AI”) programs.

During the Class Period, Defendants misled investors by touting the Company’s contracts to develop data center capabilities for AI infrastructure and falsely assuring investors that the Company’s significant capital expenditures (“CapEx”) would quickly result in accelerated revenue growth. For example, Defendants assured investors that the Company’s substantially increased spending on AI infrastructure—including for data centers used by OpenAI, the operator of ChatGPT—would rapidly convert into “accelerating revenue and profit growth” and that “we have a very good line-of-sight for our capabilities to . . . just spend on that CapEx right before it starts generating revenue.”

However, on September 24, 2025, S&P Global Ratings warned that OpenAI “could account for more than a third of total Oracle revenues by fiscal 2028 and even a greater share by fiscal 2030,” creating risks given that “OpenAI’s ability to meet contractual obligations will be contingent on AI tailwinds continuing and its models being a market leader to continue to raise external financing.” On this news, the price of Oracle common stock declined $5.37 per share, or nearly 2%, from a close of $313.83 per share on September 23, 2025, to close at $308.46 per share on September 24, 2025.

The following day, on September 25, 2025, analysts at Rothschild & Co. Redburn initiated coverage of Oracle at “Sell,” warning, among other things, that the Company’s promises of massive new revenues from its increased AI infrastructure business were “unlikely to materialize” and set a $175 price target for Oracle—representing a 40% pullback in the Company’s stock. In response, the price of Oracle common stock declined an additional $17.13 per share, or more than 5.5%, from a close of $308.46 per share on September 24, 2025, to close at $291.33 per share on September 25, 2025.

After the market closed on December 10, 2025, Oracle announced its financial results for the second quarter of fiscal year 2026, including revenue growth below analysts’ consensus estimate, quarterly CapEx well above analysts’ estimates, and negative free cash flow of more than $10 billion. During the accompanying earnings call, Defendant Douglas Kehring (the Company’s Principal Financial Officer) revealed that Oracle now projected $50 billion of CapEx in fiscal year 2026—$15 billion more than the Company’s previous projection in September 2025 and as much as $25 billion more than the Company’s projection in June 2025. Notably, despite projecting substantially increased spending, Oracle did not increase its guidance for 2026 revenue, and increased its guidance for 2027 revenues by only $4 billion.

In response to an analyst’s question about how much money Oracle needs “to raise to fund its AI growth plans ahead,” Defendant Clayton Magouyrk (the Company’s new Co-Chief Executive Officer) further stoked concerns by failing to provide a specific number and revealing only that the Company expected to spend “less” than $100 billion—suggesting that Oracle may require a massive amount of capital funding through equity raises or additional debt.

As Bloomberg and other media outlets reported that evening, the cost of protecting the Company’s debt against default for five years—a notable measure of Oracle’s credit risk—reached its highest level since April 2009. An AllianceBernstein analyst explained, “Oracle really matters because it is the harbinger of the AI capex boom,” and “[t]his repricing in debt markets is very consistent with the view that risks are building.”   On this news, the price of Oracle common stock declined $24.16 per share, or nearly 11%, from a close of $223.01 per share on December 10, 2025, to close at $198.85 per share on December 11, 2025.

After the market closed on December 11, 2025, Oracle filed its quarterly financial report on Form 10-Q with the SEC, which revealed that the Company had “$248 billion of additional lease commitments, substantially all related to data centers and cloud capacity arrangements, that are generally expected to commence between the third quarter of fiscal 2026 and fiscal 2028 and for terms of fifteen to nineteen years that were not reflected on our condensed consolidated balance sheets as of November 30, 2025.” Analysts at CreditSights later labeled this revelation a “bombshell disclosure,” noting that the Company’s lease commitments had increased massively from the prior quarter, when the Company had reported just under $100 billion in lease commitments. As Bloomberg reported, “Oracle’s future lease exposure far exceeds similar commitments by peers,” with “a mismatch between the long duration of the property leases and much shorter contracts with key customers such as OpenAI.”

On December 12, 2025, Bloomberg further reported that Oracle had “pushed back the completion dates for some of the data centers it’s developing for the artificial intelligence model developer OpenAI to 2028 from 2027” due to “labor and material shortages”—suggesting that Oracle’s promised revenue growth resulting from its increased spending may be further delayed, if it arrives at all.   In response to these revelations, the price of Oracle common stock declined $8.88 per share, or approximately 4.5%, from a close of $198.85 per share on December 11, 2025, to close at $189.97 per share on December 12, 2025.

On December 17, 2025, Financial Times reported that Blue Owl Capital—“the primary [financial] backer for Oracle’s largest data centre projects in the US”—had backed out of funding a $10 billion Oracle data center intended to serve OpenAI. According to the report, Blue Owl pulled out of the deal as a result of concerns about Oracle’s spending commitments and rising debt levels. On this news, the price of Oracle common stock declined $10.19 per share, or approximately 5.4%, from a close of $188.65 per share on December 16, 2025, to close at $178.46 per share on December 17, 2025.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Oracle’s AI infrastructure strategy would result in massive increases in CapEx without equivalent, near-term growth in revenue; (2) the Company’s substantially increased spending created serious risks involving Oracle’s debt and credit rating, free cash flow, and ability to fund its projects, among other concerns; and (3) as a result, Defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

THE LEAD PLAINTIFF PROCESS FOR ORACLE CORPORATION INVESTORS:

Oracle investors may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Oracle investors to contact the firm directly for more information about the lawsuit.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
info@ktmc.com         

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

The Bud’s For You — New York Edition

Alaskan Thunder Fuck 2G — Power, Refined

New York, NY, Feb. 21, 2026 (GLOBE NEWSWIRE) — In a market crowded with corporate messaging, outsourced customer service, and automated chatbots, one New York cannabis brand is taking a different approach.

Silly Nice, now stocked in more than 150 licensed dispensaries across New York State, is publicly releasing its direct phone number and encouraging customers to call the founders themselves.

That number is: ‪(929) 524-7033‬

Yes — the owners will answer.

Co-founders LeVar Thomas and Shane Breen are inviting customers to reach out directly when they need help finding products, understanding dosing, cooking with Diamond Powder, or simply asking questions about the brand.

In an era when consumers rarely know who owns the products they buy, Silly Nice wants to change that.

Why a Cannabis Brand Would Give Out the Owners’ Phone Number

The legal cannabis market in New York is growing rapidly. With expansion comes complexity:

• High demand restocks
• Limited inventory windows
• Dispensary sell-outs
• Varying menu updates
• Multiple product formats
• Different potency tiers

Silly Nice products frequently sell through quickly, especially high-potency offerings such as Diamond Powder, infused flower, solventless hash, and vape devices. Customers often discover that their preferred product is gone before the weekend begins.

When that happens, many brands offer email forms or social media DMs.

Silly Nice is offering something else: a direct call.

“We’re not a faceless company,” says LeVar Thomas, co-founder of Silly Nice. “If someone is spending their money on something we made, they deserve access. They deserve answers. They deserve clarity. We built this brand ourselves. We can pick up the phone.”

150 Dispensaries and Growing

With placement in more than 150 licensed New York dispensaries, Silly Nice has grown from small-batch beginnings into a statewide presence.

That growth brings momentum — and challenges.

Because Silly Nice prioritizes high-potency, terpene-forward, and transparent lab-tested products, demand frequently outpaces supply. Customers often call dispensaries only to hear that a batch sold out.

Rather than leaving buyers guessing, LeVar and Shane are encouraging customers to call them directly.

If you are looking for:

• Diamond Powder
• Frosted Hash Ball
• Papaya Wine Diamond-Frosted & Live Resin Infused Flower
• 1G Bubble Hash
• Pink Stardust 510 Cartridge
• Alaskan Thunder Fuck 2G AIO

You can call.

If you need help locating a store that still has inventory, you can call.

If you want clarity on terpene profiles or total cannabinoid percentages, you can call.

Real Help With Dosing and Cooking

High-potency cannabis requires education.

Diamond Powder, testing above 87% THC, is designed for precision. A small amount can dramatically elevate a session. When infused into food or used to enhance pre-rolls, understanding dosage becomes essential.

Customers often have questions such as:

• How much Diamond Powder should I add to an edible recipe?
• How strong is a half-gram in real terms?
• How should infused flower be dosed compared to traditional flower?
• How does solventless hash differ from vape oil in onset and duration?

These are not questions for automated support systems.

They are questions that deserve thoughtful answers.

Shane Breen explains, “We’ve seen too many brands treat customer education as optional. When you’re working with high-potency products, education is everything. If someone wants help cooking with Diamond Powder or figuring out responsible dosing, we want them to feel comfortable reaching out.”

Changing the Relationship Between Brand and Consumer

In many industries, the distance between company leadership and customers is wide.

Consumers may know the logo. They may know the packaging. But they rarely know the founders.

Silly Nice wants to shrink that gap.

LeVar Thomas adds, “Far too often you don’t know who owns the company you’re supporting. We think that’s backwards. If you support us, you should know who we are. You should know we stand behind what we make.”

This approach reflects Silly Nice’s broader philosophy of transparency:

• Lab-tested products
• Accessible Certificates of Analysis
• Cannabis-derived terpenes only
• No synthetic fillers
• Solventless extraction where applicable

Transparency is not limited to lab data. It extends to accessibility.

Why This Matters in New York Right Now

New York’s legal cannabis market is still evolving. With rapid growth comes growing pains:

• Dispensary inventory turnover
• Restock timing variability
• Product batch updates
• Menu delays

Because Silly Nice operates in a fast-moving environment where certain SKUs sell out quickly, customers sometimes need guidance navigating availability.

Rather than sending customers into search loops, the brand is offering clarity.

If a product is temporarily out of stock at one dispensary, LeVar and Shane can help direct customers to another licensed retailer carrying that batch.

The official product catalog and updated COAs are available at: sillynice.com/menu

Full brand information can be found at: sillynice.com

But sometimes a phone call is faster.

Ownership Means Accountability

Direct access to founders introduces a level of accountability rarely seen in modern retail.

When customers call ‪(929) 524-7033‬, they are speaking directly to the people responsible for:

• Product formulation
• Batch selection
• Lab verification
• Brand positioning
• Community outreach

That access fosters trust.

It also reinforces Silly Nice’s positioning as a founder-led, hands-on operation rather than a distant corporate structure.

A Culture Shift, Not a Gimmick

Releasing a public phone number is not a marketing stunt.

It is consistent with how Silly Nice operates internally.

From early production runs to statewide distribution across 150 dispensaries, the founders have remained directly involved in:

• Packaging review
• Lab analysis interpretation
• Retail partner communication
• Product education

The phone line formalizes what has already been happening behind the scenes: direct dialogue with customers.

Built for New York

New York consumers are informed, vocal, and discerning.

They:

• Compare terpene profiles
• Evaluate THC density
• Read COAs
• Ask about extraction methods
• Care about who owns the brands they support

Silly Nice was built with that customer in mind.

The brand’s high-potency offerings require responsibility. They are designed for experienced consumers who value precision.

Offering direct access to founders is an extension of that responsibility.

An Invitation

The invitation is simple:

If you need help finding product.
If you have a question about dosing.
If you want guidance cooking with Diamond Powder.
If you want clarity on infused flower strength.
If you want to understand solventless hash.

Call.

‪(929) 524-7033‬

LeVar and Shane will answer.

About Silly Nice

Founded in Harlem, Silly Nice is a premium cannabis brand focused on high-potency, terpene-forward, and lab-tested products. Now available in more than 150 licensed New York dispensaries, the brand emphasizes transparency, solventless craftsmanship where applicable, and responsible dosing education. Silly Nice offers concentrates, infused flower, solventless hash, and vape products designed for experienced consumers seeking precision and purity. For more information, visit sillynice.com or explore the full product menu at sillynice.com/menu.

Attachments

• The Bud’s For You — New York Edition
• Alaskan Thunder Fuck 2G — Power, Refined

CONTACT: Shane Breen
Silly Nice
(929) 524-7033
info@sillynice.com